A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Zocaglusagene nuzaparvovec (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms FORTIS
- Sponsors Astellas Gene Therapies
- 23 Apr 2024 Planned End Date changed from 31 Aug 2029 to 30 Sep 2029.
- 23 Apr 2024 Planned primary completion date changed from 31 Aug 2029 to 30 Sep 2029.
- 22 Feb 2024 Planned End Date changed from 30 Apr 2029 to 31 Aug 2029.